Trade Now

Capital at risk Advertisement
Share Name Share Symbol Market Type Share ISIN Share Description
Ekf Diagnostics Holdings Plc LSE:EKF London Ordinary Share GB0031509804 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  -0.90 -2.23% 39.50 1,302,574 16:29:45
Bid Price Offer Price High Price Low Price Open Price
39.50 40.20 39.60 39.40 39.50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 81.84 21.44 3.47 11.4 180
Last Trade Time Trade Type Trade Size Trade Price Currency
17:23:47 O 16,406 39.539 GBX

Ekf Diagnostics (EKF) Latest News

More Ekf Diagnostics News
Ekf Diagnostics Investors    Ekf Diagnostics Takeover Rumours

Ekf Diagnostics (EKF) Discussions and Chat

Ekf Diagnostics (EKF) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Ekf Diagnostics trades in real-time

Ekf Diagnostics (EKF) Top Chat Posts

Top Posts
Posted at 24/9/2022 09:20 by Ekf Diagnostics Daily Update
Ekf Diagnostics Holdings Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker EKF. The last closing price for Ekf Diagnostics was 40.40p.
Ekf Diagnostics Holdings Plc has a 4 week average price of 39p and a 12 week average price of 30.90p.
The 1 year high share price is 84.40p while the 1 year low share price is currently 30p.
There are currently 454,930,564 shares in issue and the average daily traded volume is 371,653 shares. The market capitalisation of Ekf Diagnostics Holdings Plc is £179,697,572.78.
Posted at 04/8/2022 20:31 by james188
faz, I think that you ask some legitimate questions in relation to the various companies that have been spun out of the Mount Sinai/EKF relationship. I should say that I am a reasonably long term investor in EKF. The share price performance of the three companies that you mention has obviously been disappointing (ditto the EKF share price), but they are all cash hungry early stage entities and I think that it is too early to make a definitive judgement. I do not think that EKF is large enough to financially further support these investments. They will all inevitably need to raise further funds and so there is a significant risk of dilution as EKF will struggle - and much more so its shareholders - to participate. EKF has much better use for its cash in growing the core business (which is doing well). It is worth noting that EKF has not spun out a further company for some time and rejected a deal that was put forward last year. That may signify a change in strategy under the new management team.
Posted at 03/8/2022 11:51 by rivaldo
Techinvest have published their new issue, so it should be OK to copy their Buy update on EKF from the July issue: "EKF Diagnostics EKF has announced the intention to distribute shares in its investment, Verici Dx, to the company’s shareholders who will receive one investment share for every 50 ordinary shares held in EKF. In order to maintain an orderly market in Verici’s shares following the distribution, the shares will be held in trust for shareholders for a period of a year. During the lock-up period, EKF Shareholders will not be permitted to transfer the legal or beneficial ownership of their Verici investment shares. Verici is a developer of advanced clinical diagnostics for organ transplant. The company is one of three business that have emerged so far from EKF’s preferred partnership agreement to develop healthcare technologies alongside Mount Sinai Health System. The other businesses are Renalytix, which is currently trading on AIM and Nasdaq, and Trellus Health. Both Trellus and Verici are listed on AIM. EKF reported owning around 5.7% of Verici’s shares at the time of the company’s final results announcement in March. The partnership with Mount Sinai is proving fruitful and represents an asset that investors may be overlooking when valuing shares in EKF. We feel that the company’s core business alone is somewhat undervalued by the current share price. Stripping out net cash of 4.6p per share, the shares trade on a prospective P/E of 14.1 for the current year, falling to 11.4 for fiscal 2023. Add in the projected value of the business investments in the Mount Sinai partnership and the stock looks excessively neglected. Buy."
Posted at 01/7/2022 14:23 by wan
'On plan' news - Industry News: EKF to highlight specific glycemic control marker at AACC 2022 EKF Diagnostics exhibiting range of tests and analyzers on Booth #3637 30 Jun 2022 EKF Diagnostics, a global in vitro diagnostics company, will be at the 2022 AACC Clinical Lab Expo, Chicago IL, July 26-28, exhibiting its range of laboratory and point-of-care diagnostics products on Booth #3637. This includes the FDA cleared Lucica® Glycated Albumin-L test kit, manufactured by Asahi Kasei Pharma Corporation and sold exclusively in the U.S. by EKF. A specific, quantitative test for glycated albumin, it is one of the most widely published methods worldwide used for the intermediate term monitoring of glycemic control in diabetes patients. Lucica® Glycated Albumin-L is an enzymatic methodology for use on compatible clinical chemistry analyzers with open channel capability, making it accurate and cost-effective to perform. It determines both glycated albumin and total albumin in separate reactions and the results are expressed as a ratio (%), minimizing differences in albumin concentrations between patients. Lucica® is also standardized to an established reference material. “The Lucica® Glycated Albumin-L is sold exclusively by EKF Diagnostics in the U.S. and complements our existing diabetes product range, offering its own utility as a specific, intermediate glycemic control marker,” said Shane O’Neill, Global Director of Scientific Affairs, EKF Diagnostics. Alongside its range of clinical chemistry tests and diagnostics analyzers, also available to view on EKF’s Booth at AACC will be its newly launched EKF Link digital connectivity solution. The downloadable software package offers secure management of point-of-care (POC) analyzers and associated data on one centralized platform. This delivers essential digital connectivity with traceability that is increasingly required for safe, secure, and effective POC testing using analyzers in many differing locations. EKF Link middleware is an open and flexible solution which can be interfaced to all vendors’ POC analyzers, including EKF’s own portfolio, to enable real-time remote management of data, including patient test results, QC results, operator management, and analyzer configuration. The user-friendly software allows POC analyzers to connect to a hospital or laboratory’s IT system, enabling data transfer from the remote analyzers for subsequent processing. This provides hospitals, laboratories, and clinicians with the functionality to manage and evaluate their patient and operator data easily and securely. EKF’s portfolio of POC diagnostic devices includes Hemo Control and DiaSpect Tm hemoglobin analyzer ranges, as well as Quo-Lab and Quo-Test HbA1c analyzers. All of these can now be digitally connected from anywhere and securely accessed remotely at any time using EKF Link, thereby enhancing their capabilities. hTTps://www.selectscience.net/industry-news/ekf-to-highlight-specific-glycemic-control-marker-at-aacc-2022/?artID=57786 Recall from the EKF Link RNS - The development and launch of EKF Link has been driven by customer demand and designed in partnership with hospital POC managers to ensure the software meets their specific needs. EKF Link provides the Company with improved competitive positioning for future POC contract tenders and new accounts, and increases the attractiveness of the EKF product portfolio to existing customers against currently available technologies. Mike Salter, CEO, of EKF Diagnostics said: "As part of our strategy to enhance our POC analyser portfolio and technology offering, we are pleased to announce that we have successfully launched EKF Link enabling practitioners to analyse their patients' results remotely, easily and securely. EKF Link provides our POC diagnostic devices with a connectivity advantage which positions us well for tenders and new accounts. This is particularly true in Europe and North America, where a connectivity solution is commonly a part of the specification. EKF Link has the added benefit that it can be installed wherever it is needed, on a PC or a central server, allowing hospitals and laboratories, technicians and clinicians to access results from various settings, reducing workload whilst increasing the security of handling patient data. "This new product launch shows our responsiveness to our customer base and increasing demand for data management capabilities. It extends the utility of our installed instrument base and provides EKF with a key advantage for further new business opportunities." hTTps://www.ekfdiagnostics.com/launch-of-ekf-link.html
Posted at 31/5/2022 05:29 by wan
EKF Diagnostics : launches middleware connectivity solution for POC analyzers and data management 05/30/2022 EKF Diagnostics announces the launch of its newEKF Link digital connectivity solution for the secure management of point-of-care (POC) analyzers and associated data on one centralized platform. An open, flexible solution, EKF Link middleware can be interfaced to all vendors' POC analyzers, including EKF's own portfolio, to enable real-time remote management of data, such as patient test results, QC results, operator management and analyzer configuration. "We designed EKF Link working together with hospital POC managers to ensure that our new middleware connectivity solution would meet their specific needs for a single, comprehensive and flexible platform to centrally manage all of their POC analyzers plus data generated," said Jo Nicol, Head of IT Solutions, EKF Diagnostics. "Our new EKF Link software delivers this essential digital connectivity with traceability that is increasingly required for safe, secure and effective POC testing using analyzers in many differing locations." Full release - hTTps://www.ekfdiagnostics.com/ekf-launches-poc-connectivity-solution.html Connect all of your analyzers on one software platform EKF Link is a middleware solution for healthcare providers to manage all of their Point of Care analyzers and the generated data on one centralized platform. EKF Link is a flexible, open solution that can be interfaced to any vendor’s Point of Care analyzer to permit the real-time management of data including patient test results, QC results, operator management and analyser configuration. EKF Link enables the transfer of data from the analyzer to the hospital or laboratory database for subsequent processing. hTTps://www.ekfdiagnostics.com/ekf-link.html
Posted at 03/5/2022 08:04 by wan
It would appear that some with vastly more insight and knowledge, namely Harwood Capital LLP and Harwood Capital Management, by raising their stake in EKF to 29.04%, can also see the much bigger picture. I repeat, in part, from a previous post - EKF was in fact trading at around these levels in share price terms for all of 2019 and the early part of 2020, but that was before the pandemic, and before the current level of investment and implementation of EKF's Growth Strategy. So, EKF have been pared back in share price terms, to pre-pandemic when the growth prospects were different (not bad), but arguably the previous and indeed new non-COVID prospects, new skills, and new customers, are not comparable to the pre-pandemic period. But unless you take a longer term view, then the fall in the share price is all you have to talk about! When you are unfortunately dealing with diagnosing and managing diseases, such as diabetes, that process does not stop, or indeed slow down.
Posted at 15/4/2022 13:41 by james188
Wan, It is pretty much the same story as for SBI, although EKF is more mature and has a broader offering. Both companies seized opportunities created by the pandemic, which more than compensated for the impact on their core businesses. They now need to fill the hole created by the inevitable fall off in COVID related revenues. I suspect that the EKF share price will remain in the doldrums until there is tangible evidence that the hole is filled. Personally, I expect that to happen and I may well add next week when the price could well fall further. One worry I have is that EKF could be taken private. Christopher Mills has form in this respect.
Posted at 15/4/2022 10:57 by wan
Stoxman...My thoughts, for what they are worth. With the general cloud hanging over the growth/biotech sector, perhaps exemplified by the fact that there is apparently a record £1.9tn on deposit in the UK at a time when deposit rates are at a record low, it's definitely risk off, but one could also argue that there is potentially a lot of dry powder in the wings. For those of us still holding the extended family of EKF stocks, on the one hand we are still better off than we were without the in-specie shares, but the overall performance thus far is disappointing to say the least. With regard to Verici in particular, clearly some investors preferred to sell rather than hold post the lock-up period, and given the dire performance, it appears they have been proven right so far. And it would also appear that the performance of Trellus is perhaps indicating that a similar post lock-up situation could occur starting next month. Personally speaking, I cooled on Trellus a while back given that they appear to be delayed, and indeed the number of companies focusing on similar/overlapping areas is presenting for a huge amount of competition. Given the unrelenting selling in Verici post lock-up, not to mention the overall performance across the holdings, and indeed the market backdrop, going forwards one wonders if the spin-off model has any immediate candidates/legs, or will indeed follow similar paths, especially if Trellus follows similar price action to Verici. In my view, Verici is in a more advanced and stronger position. There are larger players that could not only accelerate commercialisation, but that are arguably in need Verici's differentiated and litigation free products, which are underpinned by extensive scientific research and strong IP. At the very least, I am thus expecting partnerships, and I would not exclude Verici being acquired outright. A partnership deal, or a catalyst breakthrough in any one of the family could have a positive effect on the others, but we have been expecting that from Renalytix for quite some time, and clearly analysts have finally run out of patience with the management at Renalytix, which is not completely unfair, but I can see both sides of the argument. Again, in my view, it's far too early to judge the new management team, but clearly the market does not like the current forecasts, as exampled below, albeit it I think James had already highlighted such coverage a few weeks ago, so I am not sure how up to date/relevant it actually is - Some EKF Diagnostics Holdings plc (LON:EKF) Analysts Just Made A Major Cut To Next Year's Estimates By Simply Wall St Published April 14, 2022 hTTps://simplywall.st/stocks/gb/healthcare/aim-ekf/ekf-diagnostics-holdings-shares/news/some-ekf-diagnostics-holdings-plc-lonekf-analysts-just-made What I did find interesting in the above piece, was the graph, which clearly shows the expected revenue decline. Nonetheless, when you factor-out the COVID related bump, revenue growth in 2023 is quite a lot higher than pre-pandemic revenues, and overall the forecast is on a not too shabby upward trajectory. According to the chart, revenues and other financial metrics for 2024 are forecast to be similar to the COVID-boosted revenues for 2021. If we were to assume that a similar share price can be achieved to the peak in 2021 of over 80p, some would suggest that, for the patient investor, the current share price is offering a decent entry point and a dividend yield of over 3%. An important difference to consider though, is that the non-COVID related growth in revenues will be far more sustainable! I am hopeful that managements guidance has been conservative (EKF's Growth Strategy indicated such with regard to fermentation), as obviously it would be much better to resume a period of beating analysts expectations, especially with revenue increases that are sustainable.
Posted at 13/4/2022 23:15 by buywell3
wan Ref your reply about buybacks shown below Share buybacks only make sense when the NAV/share is above the current share price and therefore shares are being bought at a discount to the NAV/share. Which then could in some cases be like the company buying back its own debt at 50p in the £1. As we stand here the advfn NAV/share is BELOW the current share price so the board are literally using shareholders money to buy £1 coins for £1.50 each. advfn have the NAV at circa 20p and the buybacks have been at twice the price or 4 times the price if Net Tangible Asset Value per share were used Net Tangible Asset Value PS * 11.26 p Net Asset Value PS 20.42 p This in effect is cash wasteful and could lead to the share price falling due to the market seeing such an action as a waste of valuable capital reserves in prevailing and deteriorating market conditions . Worthy of consideration ? ---------------------------------------- wan5 Apr '22 - 09:13 - 2616 of 2648 0 1 0 Buywell...5,950,000 to be precise! I duly noted SBI's results. There is an important and fundamental difference regarding the buyback. SBI's recent acquisition, along with future earnout payments are all payable in cash. Whereas EKF's recent acquisition was satisfied by the issue of new ordinary shares at 80p+ to the value of £10mn. A similar amount of shares are now being bought back at 40p+ and held in treasury. And as my post 2612 above alludes to, the treasury shares could potentially be utilised to satisfy the ADL earnouts. And wouldn't it be good business if the shares at the various earnout anniversaries are materially higher than current buybacks, potentially meaning in my book that the treasury shares were even better value (to EKF and its investors), bearing in mind that the price per share issued to satisfy any earnout payments will be calculated using the average mid-market closing price of EKF’s shares for the five working days immediately preceding the issuance date of such shares. Obviously we don't know where the share price might be come October (1st ADL anniversary), but we know there will be news flow between now and October and we know there are various developments in the pipeline, including further execution on the Growth Strategy. So, for the purpose of an example and perhaps only for those with a positive and longer term view on EKF. Imagine a scenario where earnouts are calculated at an average mid-market closing price of EKF’s shares at 60p+ (being conservative!) when EKF are holding shares in treasury bought at 40p+. Food for thought!
Posted at 05/4/2022 09:13 by wan
Buywell...5,950,000 to be precise! I duly noted SBI's results. There is an important and fundamental difference regarding the buyback. SBI's recent acquisition, along with future earnout payments are all payable in cash. Whereas EKF's recent acquisition was satisfied by the issue of new ordinary shares at 80p+ to the value of £10mn. A similar amount of shares are now being bought back at 40p+ and held in treasury. And as my post 2612 above alludes to, the treasury shares could potentially be utilised to satisfy the ADL earnouts. And wouldn't it be good business if the shares at the various earnout anniversaries are materially higher than current buybacks, potentially meaning in my book that the treasury shares were even better value (to EKF and its investors), bearing in mind that the price per share issued to satisfy any earnout payments will be calculated using the average mid-market closing price of EKF’s shares for the five working days immediately preceding the issuance date of such shares. Obviously we don't know where the share price might be come October (1st ADL anniversary), but we know there will be news flow between now and October and we know there are various developments in the pipeline, including further execution on the Growth Strategy. So, for the purpose of an example and perhaps only for those with a positive and longer term view on EKF. Imagine a scenario where earnouts are calculated at an average mid-market closing price of EKF’s shares at 60p+ (being conservative!) when EKF are holding shares in treasury bought at 40p+. Food for thought!
Posted at 05/4/2022 08:10 by buywell2
6M buybacks and only another 3M left is that not correct Then quite a long wait for the next tranche if it gets the nod Interestingly SBI have not announced an initial/interim buyback program like EKF What say you wan ? 05 Apr 2022 7:00 am RNS Factsheet EKF Diagnostics Hldg (EKF) Purchase of Own Shares 04 Apr 2022 7:00 am RNS Factsheet EKF Diagnostics Hldg (EKF) Purchase of Own Shares 01 Apr 2022 7:00 am RNS Factsheet EKF Diagnostics Hldg (EKF) Purchase of Own Shares 31 Mar 2022 7:00 am RNS Factsheet EKF Diagnostics Hldg (EKF) Purchase of Own Shares 30 Mar 2022 7:00 am RNS Factsheet EKF Diagnostics Hldg (EKF) Purchase of Own Shares 29 Mar 2022 7:01 am RNS Factsheet EKF Diagnostics Hldg (EKF) Share Buyback Programme 7:00 am RNS Factsheet EKF Diagnostics Hldg (EKF) Final Results
Ekf Diagnostics share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
EKF
Ekf Diagno..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220925 01:09:53